Featured Research

from universities, journals, and other organizations

New evidence on co-prescribing for heart and stroke patients

Date:
April 23, 2010
Source:
University of East Anglia
Summary:
New research shows no risk in combining two commonly-prescribed treatments for patients at risk of heart attacks and strokes.

New research by the University of East Anglia (UEA) shows no risk in combining two commonly-prescribed treatments for patients at risk of heart attacks and strokes.

Published this month in the journal Alimentary Pharmacology & Therapeutics, the study is the largest investigation yet into concerns of an adverse interaction between Proton Pump Inhibitors (PPIs) and the antiplatelet drug clopidogrel.

The researchers analysed data from 23 large randomised clinical trials involving more than 90,000 patients worldwide. It concluded that co-prescribing the two drugs caused no adverse effect.

"Recent studies have suggested that patients receiving clopidogrel will not get the full effect of the treatment if they are also taking PPIs," said lead author Dr Yoon Loke, of UEA's School of Medicine. "The aim of our study was to determine the actual effect of the treatment combination on cardiovascular outcomes and mortality.

"Our findings showed no evidence of any effect on overall mortality and no associated risk with the co-prescribing of these agents. It is therefore premature to impose a blanket policy of withdrawal or avoidance of PPI use in patients taking clopidogrel. Clinicians should instead re-focus on a patient's susceptibility to gastric bleeding and not lose sight of the fact that some patients with high gastrointestinal risk may genuinely benefit from PPI therapy."

Patients at risk of heart attack or stroke are routinely prescribed antiplatelet therapy to prevent harmful blood clots. Although the effectiveness of this treatment is well-documented, it can cause bleeding in the stomach, which is potentially life-threatening. Co-prescribing PPIs substantially decreases this risk.

The findings of this new meta-analysis by UEA are in direct contrast to the ongoing safety review by the US Food and Drug Administration (FDA), which has advised health professionals to avoid the concomitant use of clopidogrel and omeprazole (a PPI).

However, the FDA's findings are based on laboratory data rather than a thorough review of actual clinical outcomes in patients.

In the United Kingdom, around 100,000 patients are admitted to hospital each year with heart attack or stroke. In the United States, more than 1.5 million people per year are affected. Patients are typically treated with aspirin and/or clopidogrel, which may cause side effects such as stomach ulcers and bleeding. Proton pump inhibitors are used to prevent gastrointestinal bleeding, and these are one of the most commonly-prescribed classes of drug in the world, costing 425m in England and 7bn globally in 2006.


Story Source:

The above story is based on materials provided by University of East Anglia. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. S. Kwok, Y. K. Loke. Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Alimentary Pharmacology & Therapeutics, 2010; DOI: 10.1111/j.1365-2036.2010.04247.x

Cite This Page:

University of East Anglia. "New evidence on co-prescribing for heart and stroke patients." ScienceDaily. ScienceDaily, 23 April 2010. <www.sciencedaily.com/releases/2010/04/100408105156.htm>.
University of East Anglia. (2010, April 23). New evidence on co-prescribing for heart and stroke patients. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2010/04/100408105156.htm
University of East Anglia. "New evidence on co-prescribing for heart and stroke patients." ScienceDaily. www.sciencedaily.com/releases/2010/04/100408105156.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins